These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29069826)

  • 21. circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252.
    Zhang S; Cheng J; Quan C; Wen H; Feng Z; Hu Q; Zhu J; Huang Y; Wu X
    Mol Ther Nucleic Acids; 2020 Mar; 19():718-730. PubMed ID: 31945729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long Noncoding RNA TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells.
    Gu L; Li Q; Liu H; Lu X; Zhu M
    Onco Targets Ther; 2020; 13():2007-2019. PubMed ID: 32189969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.
    Wang Y; Wu N; Zhang J; Wang H; Men X
    Onco Targets Ther; 2020; 13():4089-4097. PubMed ID: 32494162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Silencing of circHIPK3 Sensitizes Paclitaxel-Resistant Breast Cancer Cells to Chemotherapy by Regulating HK2 Through Targeting miR-1286.
    Ni J; Xi X; Xiao S; Xiao X
    Cancer Manag Res; 2021; 13():5573-5585. PubMed ID: 34285578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2.
    Chen X; Zhang X; Qian Y; Xia E; Wang Y; Zhou Q
    Cell Cycle; 2022 May; 21(10):1058-1076. PubMed ID: 35184686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circular RNA circ_0000376 promotes paclitaxel resistance and tumorigenesis of non-small cell lung cancer via positively modulating KPNA4 by sponging miR-1298-5p.
    Hu S; Zhang Q; Sun J; Xue J; Wang C
    Thorac Cancer; 2023 Aug; 14(22):2116-2126. PubMed ID: 37455373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
    Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
    Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circ_0069094 regulates malignant phenotype and paclitaxel resistance in breast cancer cells via targeting the miR-136-5p/YWHAZ axis.
    Kong Z; Han Q; Zhu B; Wan L; Feng E
    Thorac Cancer; 2023 Jul; 14(19):1831-1842. PubMed ID: 37192740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of Circular RNA Hsa_circ_0000714 Can Regulate RAB17 by Sponging miR-370-3p to Reduce Paclitaxel Resistance of Ovarian Cancer Through CDK6/RB Pathway.
    Guo M; Li S; Zhao X; Yuan Y; Zhang B; Guan Y
    Onco Targets Ther; 2020; 13():13211-13224. PubMed ID: 33380810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circ_0000231 promotes paclitaxel resistance in ovarian cancer by regulating miR-140/RAP1B.
    Liu J; Wang H; Xiao S; Zhang S; Qi Y; Wang M
    Am J Cancer Res; 2023; 13(3):872-885. PubMed ID: 37034216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circ_0011292 Enhances Paclitaxel Resistance in Non-Small Cell Lung Cancer by Regulating miR-379-5p/TRIM65 Axis.
    Guo C; Wang H; Jiang H; Qiao L; Wang X
    Cancer Biother Radiopharm; 2022 Mar; 37(2):84-95. PubMed ID: 32833503
    [No Abstract]   [Full Text] [Related]  

  • 34. CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
    Ying H; Zhao R; Yu Q; Zhang K; Deng Q
    Drug Dev Res; 2022 Apr; 83(2):512-524. PubMed ID: 34541682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis.
    Wei S; Qi L; Wang L
    Anticancer Drugs; 2021 Jun; 32(5):496-507. PubMed ID: 33735118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
    Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
    Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of circNRIP1 Suppresses the Paclitaxel Resistance of Ovarian Cancer via Regulating the miR-211-5p/HOXC8 Axis.
    Li M; Cai J; Han X; Ren Y
    Cancer Manag Res; 2020; 12():9159-9171. PubMed ID: 33061608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.
    Zhang J; Guan W; Xu X; Wang F; Li X; Xu G
    Oncogene; 2021 Jul; 40(30):4906-4918. PubMed ID: 34163033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells.
    Li L; Xu QH; Dong YH; Li GX; Yang L; Wang LW; Li HY
    Eur Rev Med Pharmacol Sci; 2016 May; 20(10):2004-10. PubMed ID: 27249598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blocking circ_0010235 suppresses acquired paclitaxel resistance of non-small cell lung cancer by sponging miR-512-5p to modulate FAM83F expression.
    Li Y; Ma Z; Luo M; Liang R
    Anticancer Drugs; 2022 Nov; 33(10):1024-1034. PubMed ID: 36206095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.